Abstract

Background: Integrase inhibitors (INIs)-based antiretroviral therapies (ART) are more recommended than efavirenz (EFV)-based ART for people living with HIV/AIDS (PLWHA). Yet, the advantage of integrase inhibitors in treating TB/HIV coinfection is uncertain. Therefore, the objective of this systematic review is to evaluate the effects and safety of INIs-versus EFV-based ART in TB/HIV coinfection, and demonstrate the feasibility of the regimens.

Methods: Four electronic databases were systematically searched through September 2020. Fixed-effects models were used to calculate pooled effect size for all outcomes. The primary outcomes were virologic suppression and bacteriology suppression for INIs-versus EFV-based ART. Secondary outcomes included CD4+ cell counts change from baseline, adherence and safety.

Results: Three trials (including 672 TB/HIV patients) were eligible. ART combining INIs and EFV had similar effects for all outcomes, with none of the point estimates argued against the INIs-based ART on TB/HIV patients. Compared to EFV-based ART as the reference group, the RR was 0.94 (95% CI 0.85 to 1.05) for virologic suppression, 1.00 (95% CI 0.95 to 1.05) for bacteriology suppression, 0.98 (95% CI 0.95 to 1.01) for adherence. The mean difference in CD4+ cell counts increase between the two groups was 14.23 cells/μl (95% CI −6.40 to 34.86). With regard to safety (adverse events, drug-related adverse events, discontinuation for drugs, grade 3–4 adverse events, IRIS (grade 3–4), and death), INIs-based regimen was broadly similar to EFV-based regimens. The analytical results in all sub-analyses of raltegravir (RAL) and dolutegravir (DTG)-based ART were valid.

Conclusion: This meta-analysis demonstrates similar efficacy and safety of INIs-based ART compared with EFV-based ART. This finding supports INIs-based ART as a first-line treatment in TB/HIV patients. The conclusions presented here still await further validation owing to insufficient data.

Keywords: Integrase inhibitors, Efavirenz, Raltegravir, Dolutegravir, TB, HIV patients
Integrase inhibitors (INIs), mainly include raltegravir (RAL) and dolutegravir (DTG), exhibit good efficacy and safety, and are superior to PIs in terms of durability [24]. Since there is no need to add ritonavir boosting like PIs, in high-income countries, RAL and DTG are preferred first-line ART for the treatment-naive and treatment-experienced PLWHA. Commendably, a breakthrough low price agreement, which provides accessibility drugs in low- and middle-income countries was achieved in 2017 [25]. INIs cite better efficacy, reduce treatment discontinuation, and serve as a higher genetic barrier to resistance than efavirenz-based ART [26]. INIs, the substrate by several metabolic enzymes for UGT1A1 and cytochrome CYP3A, are also affected by RIF induction. When co-administered with RIF, there are substantial reductions in the blood concentration of INIs, and hence doubling the dose of both drugs can overcome the induction by RIF [27, 28]. As a hypothesis, INIs-based ART may be more favorable than EFV-based ART in TB/HIV patients. Currently, little data are available regarding the effect of INIs on TB/HIV patients [29]. There is no clinical evidence to support switching patients from the EFV-based regimen directly to the INIs-based regimen [30]. To provide a best available evidence, and refine the existing clinical guidelines, we collected a limited number of randomized controlled trials (RCTs), compared INIs- and EFV-based ART according to the principles of evidence-based medicine.

Methods
Study design
The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [31].

Data sources and searches
PubMed, Medline, Embase, and Cochrane Library until 17 September 2020 were systematically searched. Studies were limited to the English language. Using the following keywords: ‘tuberculosis’, ‘raltegravir’, ‘dolutegravir’, and ‘integrase inhibitor’. We used the names of two available INIs drugs as keywords, as both drugs are the primarily recommended drugs.

RCTs that compared ART in INIs- with EFV-based, in TB/HIV patients with treatment-naive, and evaluated at least one outcome of effectiveness and/or safety. The INIs included DTG and RAL, while EFV-based ART was the preferred therapeutic regimen. All patients received a standard tuberculosis treatment regimen with isoniazid, rifampicin, pyrazinamide, and ethambutol for the first 2 months, followed by isoniazid and rifampicin for the subsequent 4 months. Rifampicin was given at a dose

increases the risk of progression to active TB disease [3], which challenges the goal of the “90–90–90” targets of HIV by 2020 and the end TB strategy by 2035. A novel strategy recommending a 6 months of isoniazid preventive therapy (IPT) on PLWHA is essential in preventing latent TB progressing into active disease from latent TB, and will reduce both the incidence and subsequently mortality of TB [4].

People with TB/HIV co-infection typically present with low CD4+ cell counts and high HIV viral loads. TB/HIV patients require co-treatment for both diseases, in particular for the TB [5]. During this critical period, effective management of the two diseases is essential to improve the survival and quality of life for co-infection patients. However, co-treatment with TB and HIV is challenging, owing to drug interactions, overlapping toxicities, and a high risk of immune reconstitution inflammatory (IRIS) [6]. Among these factors, drug interaction between antiretroviral and antituberculosis greatly counteracts the antiretroviral therapy.

Rifampicin (RIF), the standard TB treatment regimen of four chemical drugs, remains the first choice, irrespective of the patient’s HIV status [5]. Although an increasing number of new antituberculosis drugs are available to treat HIV infection, only a few can be used in patients with co-infection due to the drug-drug interactions. In countries with limited resources and a high burden of TB, efavirenz (EFV) and nevirapine (NVP) are the preferable options for initial antituberculosis treatments (ART) in TB/HIV co-infection [7]. Due to the high rate of virological failure and adverse reactions [8–10], NVP is not recommended as a preferred therapy for the antiviral treatment of TB/HIV patients. While EFV metabolism is affected by certain genetic polymorphisms [11] with high inter-patient variations in plasma concentrations. When combined with RIF, the effect may magnify [12–14]. Some studies recommend increasing the dosage of EFV to counteract the inductive effects of RIF [15, 16], but there is no sufficient evidence to support the efficacy of this approach [14, 17, 18]. Besides, there remain several challenges about EFV, such as EFV-related adverse effects and drug resistance [19, 20]. In the event of contraindications or intolerance to EFV, it is urgent to find a novel alternative agent. Protease inhibitors (PIs) may offer a solution to these problems and even additional advantages [21]. Noteworthy, PIs needs to be rifabutin (RBT) fixed collocation to co-treat TB/HIV, but the optimal RBT dosing frequency is unknown [22, 23]. TB treatment is usually given in fixed-dose combinations, and considering the cost or non-availability of RBT, it is difficult to substitute RBT for RIF in many settings.
of 10 mg per kg per day. In case of extrapulmonary TB, the duration of the maintenance regimen was extended. Antiretroviral treatment was started after 2–8 weeks of TB treatment.

We ignored results with a follow-up length shorter than 48 weeks (e.g. 24 weeks), which was not sufficient for evaluating clinically significant outcomes for intervention. The timeframe was applied in the previous systematic reviews on HIV treatment [32]. If the same study were overlapped in multiple publications, only the complete or most recent literature was included in the present study.

After removal of duplicates, all studies identified in the search were screened by title and abstract by two independent reviewers (YS and ZD), then full-texts were reviewed to determine eligibility. All the inappropriateness was resolved by group discussion or a third reviewer (CQ).

Data extraction and quality assessment
Data extracted included: (1) research characteristics (author, year of publication, study design, and sample size); (2) patient demographics (age, sex, and race) and baseline characteristics (CD4+ cell counts, viral load); and (3) result at the end of the study.

The risk of bias was evaluated the Cochrane Collaboration tool [Cochrane Handbook for Systematic Reviews of Intervention, version 5.1.0]. Assessed risk of bias included six specific domains: sequence generation, allocation concealment, blinding, incomplete data, selection outcome reporting, and other possible biases. The risk of bias in each domain was judged as “low risk”, “high risk”, or “unclear risk”, with the last category bias indicating either lack of information or uncertainty over the potential source of bias.

Outcomes
Efficacy
The primary efficacy outcomes were the percentages of participants with virologic and bacteriology suppression at week 48. The response was assessed using a modified US FDA Snapshot algorithm [33], in which participants with HIV-1 RNA ≥ 50 copies/ml or without HIV-1 RNA data at week 48 were both considered as non-responders. Another primary outcome was TB treatment outcomes according to WHO definitions [34]. The secondary efficacy outcomes were the mean increase in CD4+ cell counts from baseline and the ratio of adherence at Week 48.

Safety
Safety outcomes included the percentage of participants with adverse events (AEs), drug-related AEs, discontinuation for drugs, grade 3–4 AEs, IRIS (grade 3–4), and death during the 48 weeks.

Data analysis
EFV-based ART was used as the reference group in the meta-analysis. For continuous outcomes (that is, CD4+ cell counts) in this systematic review, for efficient merging, the median and interquartile range (IQR) were converted into mean and standard deviation (SD) [35, 36]. A difference in mean change greater than 0 favored INIs-based ART. For the dichotomous outcomes, a risk ratio (RR) with 95% confidence interval (CI) was calculated based on the number of total participants and the number of events in each group within each study. Then the studies was pooled to obtain an overall effect estimate. A RR greater than 1 favored INIs-based ART for all dichotomous outcomes. To evaluate the consistency of INIs, in studies with predefined subgroups, we only performed subgroup analysis including DTG and RAL.

Statistical heterogeneity among the studies was measured by the Cochrane Q test and I² statistic. To account for the heterogeneity across the studies, the fixed-effect model was used to combine the effect estimate from included studies.

The possibility of publication bias estimated by funnel plots was not performed, because the number of studies included in the meta-analysis was fewer than 10. In such a case, the funnel plots could yield misleading results and therefore were not recommended.

All data analyses were performed with Review Manager 5.4 (Cochrane Collaboration, London, UK).

Results

The flow chart summarized the detailed retrieval steps (Fig. 1). We initially identified 452 articles from four databases. By screening titles, abstracts, and full texts, finally three eligible clinical trials (reported in 3 published articles and 3 clinical trial registration) were included in this meta-analysis.

The main features of the included studies are summarized in Additional file 1: Table S1. 672 treatment-naïve patients receiving a standard TB treatment regimen were randomized in the three trials. In the ANRS 12,180 [37, 38] and ANRS 12,300 [39, 40] trials, RAL plus TDF/3TC was compared with EFV plus TDF/FTC. While in the INSPIRING [41, 42] trial, DTG was compared with EFV plus major TDF/FTC, or plus other two N(t)RTIs. Drug doses of INIs (i.e. DTG and RAL) were double-dosed (twice-daily). All studies’ analyses were open-label, randomized, and noninferiority clinical trials. Only one trial did allocation concealment. All trials did not described blinding of outcome assessment. One determine the exception of the blinding of participants...
and personnel because of the open-label nature of all study design (see Additional file 2: Fig. S1 and Additional file 3: Fig. S2).

**Efficacy**

None of the INIs-based group was significantly less than any of the EFV-based group on any of the efficacy outcomes assessed (Table 1). As shown in this Meta-analysis, INIs and EFV groups had similar effects on all critical outcomes, with none of the point estimates argued against the INIs-based ART. In the intent-to-treat (ITT) population, 231 patients on INIs (66%) and 223 patients on EFV (69.3%) had HIV-RNA < 50 copies/ml. The overall RR in the pooled proportion of virologic suppression between two regimens was 0.94 (95% CI 0.85 to 1.05). Bacteriology suppression, another key outcome,

| Outcome or subgroup       | Studies | Cases | No. with event/total no. of patients INIs and EFV | Effect estimate (RR and 95% CI) |
|---------------------------|---------|-------|--------------------------------------------------|--------------------------------|
| Virologic suppression     | 3       | 672   | 231/350 and 223/322                              | 0.94 (0.85, 1.05)              |
| DTG vs. EFV               | 1       | 113   | 52/69 and 36/44                                 | 0.92 (0.76, 1.12)              |
| RAL vs. EFV               | 2       | 559   | 179/281 and 187/278                             | 0.95 (0.84, 1.07)              |
| Bacteriology suppression  | 3       | 672   | 313/350 and 288/322                             | 1.00 (0.95, 1.05)              |
| DTG vs. EFV               | 1       | 113   | 61/69 and 40/44                                 | 0.97 (0.86, 1.10)              |
| RAL vs. EFV               | 2       | 559   | 252/281 and 248/278                             | 1.01 (0.95, 1.06)              |
| Adherence                 | 3       | 617   | 309/321 and 291/296                             | 0.98 (0.95, 1.01)              |
| DTG vs. EFV               | 1       | 99    | 56/58 and 38/41                                 | 1.04 (0.94, 1.15)              |
| RAL vs. EFV               | 2       | 518   | 253/263 and 253/255                             | 0.97 (0.94, 1.00)              |
showed an overall RR of 1.00 (95% CI 0.95 to 1.05). The conclusion from these two primary efficacy outcomes was consistent. Poor adherence to antiretroviral therapy could contribute to HIV treatment failure, while in both groups, the adherence was high and similar with an overall RR was 0.98 (95% CI 0.95 to 1.01). The mean increase in CD4+ cell counts from baseline to Week 48 was 201.2 cells/μl for the INIs group and 184.3 cells/μl for the EFV group [mean difference 14.23 cells/μl (95% CI -6.40 to 34.86), Fig. 2].

Safety

The occurrence of all AEs was similar in patients between the two groups (Table 2). Compared to control, the incidence of drug-related AEs of INIs-based group was lower, but these difference was not statistically significant between the two groups. Co-treatment could elicit a serious condition called IRIS in TB/HIV patients. The occurrence of IRIS (grade 3–4) observed in three studies was infrequent. The overall RR was 0.63 (95% CI 0.32 to 1.25) between the two groups.

Since publication bias was hard to detect when the number of studies was small, publication bias was not examined.

Discussion

This meta-analysis pooled data from 3 trials, showing that in TB/HIV patients, the effects of INIs-based ART was non-inferior to EFV-based ART. Two primary efficacy outcomes (virologic and bacteriology suppression) were effectively controlled. Prespecified subgroup analyses suggested that these results were robust in DTG- and RAL-containing ART. Two retrospective cohort studies [43, 44] were excluded from this meta-analysis, owing to their non-RCT nature. In these two studies, it was showed that INIs was associated with favorable TB

![Fig. 2 Forest plot of compared CD4+ cell counts recovery with the two regimens at 48 weeks](image)

### Table 2

Summary of the pooled safety outcome

| Outcome or subgroup | Studies | Cases | No. with event/total no. of patients INIs and EFV | Effect estimate (RR and 95% CI) |
|---------------------|---------|-------|-----------------------------------------------|--------------------------------|
| Any AEs             | 2       | 215   | 98/120 and 86/95                             | 0.92 (0.76, 1.11)            |
| DTG vs. EFV         | 1       | 113   | 52/69 and 40/44                              | 0.83 (0.70, 0.98)            |
| RAL vs. EFV         | 1       | 102   | 46/51 and 46/51                              | 1.00 (0.88, 1.14)            |
| Drug-related AEs    | 3       | 674   | 50/349 and 54/325                             | 0.80 (0.57, 1.14)            |
| DTG vs. EFV         | 1       | 113   | 19/69 and 14/44                              | 0.87 (0.49, 1.54)            |
| RAL vs. EFV         | 2       | 561   | 31/280 and 40/281                             | 0.78 (0.50, 1.21)            |
| Discontinuation for drugs | 3 | 674 | 2/349 and 8/325 | 0.30 (0.08, 1.09) |
| DTG vs. EFV         | 1       | 113   | 0/69 and 2/44                                | 0.13 (0.01, 2.62)            |
| RAL vs. EFV         | 2       | 561   | 2/280 and 6/281                              | 0.39 (0.09, 1.64)            |
| Grade 3–4 AEs       | 3       | 674   | 78/349 and 87/325                             | 0.89 (0.68, 1.15)            |
| DTG vs. EFV         | 1       | 113   | 3/69 and 2/44                                | 0.96 (0.75, 1.50)            |
| RAL vs. EFV         | 2       | 561   | 75/280 and 85/281                             | 0.89 (0.68, 1.15)            |
| IRIS (Grade 3–4)    | 3       | 674   | 13/349 and 20/325                             | 0.63 (0.32, 1.25)            |
| DTG vs. EFV         | 1       | 113   | 1/69 and 1/44                                | 0.64 (0.04, 9.93)            |
| RAL vs. EFV         | 2       | 561   | 12/280 and 19/281                             | 0.63 (0.31, 1.28)            |
| Death               | 3       | 672   | 13/350 and 16/322                             | 0.80 (0.39, 1.64)            |
| DTG vs. EFV         | 1       | 113   | 0/69 and 0/44                                | NA                            |
| RAL vs. EFV         | 2       | 559   | 13/281 and 16/278                             | 0.80 (0.39, 1.64)            |
treatment outcome and viral suppression, which was similar to our study. We also had several key secondary findings. First, as PLWHA without infection TB [45], INIs had more motivation in terms of CD4+ recovery compared with EFV. INIs had the trend of increasing in CD4+ cell counts (14.23 cells/μl, 95% CI −6.40, 34.86) when compared with EFV was observed in the present study, but there was no statistically significant difference. This finding was similar to the outcomes in cohort studies [44]. However, in co-infected patients, anti-TB treatment could not restore the immune response, and the HIV-related changes dominate the overall immunological picture [46]. More data are therefore needed to validate our hypothesis. Second, compared with EFV, INIs was not more favorable in improving medication adherence. Though the pill burden and cumulative toxicity could be translated into suboptimal adherence, the two groups both had good adherence at 48 Week. Similar results were also obtained in three antiretrovirals treatment for PLWHA [26]. This might be related to more detailed ART consultation for subjects at the initiation of the trial, which promoted the adherence [47]. Besides, patients whose treatment was discontinued due to drug toxicity were few in our study, since the RIF reduced the concentrations of antiretroviral drugs, which then alleviated the toxic side effects. The effectiveness of adherence also assured treatment satisfaction. It is noteworthy, a recent meta-analysis [48] showed RAL-based dual treatment was more conducive to adherence enhancement in PLWHA, suggesting that simplified treatment could also contribute to adherence. Yet, there is currently a lack of such studies in the TB/HIV patients. Taken together, all the efficacy outcomes assessed, none of the EFV-based ART was statistically significantly better than that of the INIs-based ART.

Since more combinations of anti-TB and antiretroviral drugs are being used, the drug toxicity in TB/HIV patients could be of concern. The incidences of AEs in both groups were high, and the main adverse events were serious (grade 3–4). Unexpectedly, the drug-related adverse events were relatively rare. INIs-based ART can achieve fast decrease of the HIV viral load, which gives high expectations regarding immune activation or inflammation recovery. But there is also concern that the drugs may lead to an increased rate of IRIS [49]. Actually, compared to EFV, a lower incidence of IRIS (grade 3–4) in the INIs group showed that IRIS was uncommon, also indicating the reliability of our findings. Multiple systematic reviews [50–52] showed that INIs were effective in improving clinical outcomes in PLWHA. Unfortunately, there lacked monitoring data to evaluate the effect of INIs treatment on TB/HIV patients. This meta-analysis provides an important evidence in this regard. In the included studies, INIs only contained DTG and RAL, the two most representative INIs universally recommended as first-line therapy by current guidelines. Both drugs showed similar efficacy [53], which was no inferior to EFV, as shown by the subgroup analyses of this meta-analysis. Furthermore, the subgroup analyses of other efficacy endpoints revealed the same results suggesting that these two drugs are suitable for the co-treatment of TB/HIV patients.

This meta-analysis had a few limitations. Firstly, the number of included studies was very small. We were unable to perform certain subgroup analyses such as the race, since the results have not reported in individual studies. It restricts the generalizability of these results but not their validity. Secondly, patients with ART-experienced were not included in the analysis due to the insufficient study data. We were unable to assess the efficacy in TB/HIV patients who were switched from an EFV to an INIs regimen. Finally, we could not rule out the possibility of publication bias due to the small number of studies.

Conclusion
In this meta-analysis, the effects of INIs-based ART are equivalent to EFV-based ART in treatment-naïve of TB/HIV patients. Our finding supports recommending INIs-based ART as first-line treatment in TB/HIV patients, especially under the current guidelines. We hypothesize that INIs-based ART may be more favorable than EFV-based ART, according to the evidence from studies of PLWHA without TB infection. After these ongoing studies [54] are completed and published, we will do further research to validate our hypothesis.

Abbreviations
AIDS: Acquired immune deficiency syndrome; AEs: Adverse events; ART: Antiretroviral therapies; CI: Confidence interval; DTG: Dolutegravir; EFV: Efavirenz; HIV: Human immunodeficiency virus; INIs: Integrase inhibitors; IPT: Isoniazid preventive therapy; IQR: Interquartile range; IRIS: Immune reconstitution inflammatory; ITT: Intent-to-treat; NVP: Nevirapine; PI: Protease Inhibitors; PLWA: People living with HIV/AIDS; RAL: Raltegravir; RBT: Rifabutin; RCTs: Randomized Controlled Trials; RIF: Rifampicin; RR: Risk ratio; SD: Standard deviation; TB: Tuberculosis.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12981-021-00348-w.

Additional file 1: Table S1. Main characteristic of included studies.

Additional file 2: Fig S1. Risk of bias graph. Quality assessment about each risk of bias item.

Additional file 3: Fig S2. Risk of bias summary. Judgment of the risk of bias for each included study with Cochrane quality assessment tool.

Acknowledgements
Not applicable.
Authors' contributions

CQ and MH conceived and designed the research, YS and ZD acquired the data, performed statistical analysis, YS drafted and approved the manuscript submitted. HW and YC carried out study search, LY and YD extracted data, XT and KZ conducted quality assessment, ZS revised the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by the Natural Science Foundation of Hunan Province, China (2017JJ3250 and 2019JJ40230) and Project of Science and Technology of Health Commission of Hunan Province, China (B2019034 and B2019035) and Bethune-Medical Scientific Research Foundation (SCZ049BS).

Availability of data and materials

Data are available from the authors on request.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors have disclosed that they have no significant relationships with, or financial interest in, any other commercial companies pertaining to this article. CQ received grants from the Natural Science Foundation of Hunan Province, China (2017JJ3250), and Project of Science and Technology of Health Commission of Hunan Province, China (B2019034); XZ received grants from the Natural Science Foundation of Hunan Province, China (2019JJ40230), and Project of Science and Technology of Health Commission of Hunan Province, China (B2019035); LY received grants from the Bethune Medical Scientific Research Foundation (SCZ049BS); the other authors had no financial relationships with any organisations; no other relationship or activities that could appear to have influenced the submitted work.

Author details

1 Department of Evidence-Based Medicine and Clinical Center, The First People's Hospital of Huaihua, University of South China, Huaihua 418000, People's Republic of China. 2 Department of Clinical Pharmacy, The First People's Hospital of Huaihua, University of South China, Huaihua 418000, People's Republic of China. 3 Department of Intensive Care Unit, The First People's Hospital of Huaihua, University of South China, Huaihua 418000, People's Republic of China. 4 Department of General Practice, The First People's Hospital of Huaihua, University of South China, Huaihua 418000, People's Republic of China. 5 Hunan University of Medicine, Huaihua 418000, People's Republic of China.

Received: 23 November 2020 Accepted: 12 April 2021

Published online: 01 May 2021

References

1. WHO. Three Is meeting: intensified case finding (ICF), isoniazid preventive therapy (IPT) and TB infection control (IC) for people living with HIV. Geneva: WHO; 2008.

2. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS. 2001;15(2):143–52.

3. Djoba Sawaya JF, Ruhwald M, Eugen-Olsen J, Walzl G. Correlates for disease progression and prognosis during concurrent HIV/TB infection. Int J Infect Dis. 2007;11(4):289–99.

4. Hakim J, Musiime V, Szubert AJ, Mallewa J, Silka A, Agutu C, et al. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. N Engl J Med. 2017;377(3):233–45.

5. Manosuthi W, Wilboonchutikul S, Sungkanuparph S. Integrated therapy for HIV and tuberculosis. AIDS Res Ther. 2016;13(1):1–2.

6. Manosuthi W, Wilboonchutikul S, Sungkanuparph S. Integrated therapy for HIV and tuberculosis. AIDS Res Ther. 2016;13:22.
25. UNAIDS. New high-quality antiretroviral therapy to be launched in South Africa, Kenya and over 90 low- and middle-income countries at reduced price. https://www.unaids.org/en/resources/presscentre/pressreleasesandstatements/archive/2017/september/20170921_TLD
26. Walmsley SL, Antela A, Clumeck N, Ducuicseu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–18.
27. Taburet AM, Sauvageon H, Grinsztejn B, Assuied A, Veloso V, Pilotto JH, et al. Pharmacokinetics of raltegravir in HIV-infected patients on rifampicin-based antiretroviral therapy. Clin Infect Dis. 2015;61(8):1328–35.
28. Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampicin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62(1):21–7.
29. Donward J, Lessells R, Drain PK, de Oliveira T, Pillay Y, et al. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. Lancet HIV. 2018;5(7):e400–4.
30. Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter F, et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? AIDS. 2018;32(12):1511–61.
31. Shamseer L, Moher D, Clarke M, Gherisi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.
32. Feng Q, Zhou A, Zou H, Ingle S, May MT, Cai W, et al. Quadruple versus triple combination antiretroviral therapies for treatment-naive people with HIV: systematic review and meta-analysis of Randomised Controlled Trials. BMJ. 2019;366:l7179.
33. US DHSS, CDER. Human Immunodeficiency Virus–1 Infection: Developing Antiretroviral Drugs for Treatment Guidance for Industry. 2015; https://www.fda.gov/media/86284/download. Accessed 9 Mar 2021.
34. WHO. Tuberculosis care with TB-HIV co-management. 2007; https://www.who.int/hiv/pub/ima/TB_HIVModule230507?pdf=pdf [Accessed 9 October 2020].
35. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
36. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–805.
37. Grinsztejn B, De Castro N, Arnold V, Veloso VG, Morgado M, Pilotto JH, et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, Randomised Trial. Lancet Infect Dis. 2014;14(6):459–67.
38. Nct. Efficacy and safety of 2 raltegravir doses in Naive HIV-1-infected patients on rifampicin-based antiretroviral therapy. ClinicalTrials.gov show/NCT00822312009.
39. De Castro N, Marcy O, Chazzlon C, Messiou E, Holée S, N’Takpe JB, et al. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Refflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial. Lancet Infect Dis. 2021. https://doi.org/10.1016/S1473-3099(20)30869-0.
40. Nct. Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis. 2014. https://clinicaltrials.gov/show/nct02273765.
41. Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and human immunodeficiency virus: a multi-center, noncomparative, open-label, Randomized Trial. Clin Infect Dis. 2020;70(4):549–56.
42. Nct. Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) – Tuberculosis (TB) Co-infection. 2014. https://clinicaltrials.gov/show/nct02178592.
43. Modongo C, Wang Q, Dimu M, Matsui O, Kgwaadira B, Rangkoane-Pono G, et al. Clinical and virological outcomes of TB/HIV coinfected patients treated with dolutegravir-based HIV antiretroviral regimens: programmatic experience from Botswana. J Acquir Immune Defic Syndr. 2019;82(2):111–5.
44. Pinho REG, Pascon ARP, Alves K, Oliveira PB, Menezes AJ, Perini FR, et al. CD4 count and viral load dynamics under different art regimens in HIV/TB coinfection. Topics Antiviral Med. 2020;28(1):273.
45. Rutherford GW, Horvath H. Dolutegravir plus two nucleoside reverse transcriptase inhibitors versus efavirenz plus two nucleoside reverse transcriptase inhibitors as initial antiretroviral therapy for people with HIV: a systematic review. PLoS ONE. 2016;11(10):e0162775.
46. Mihret A, Abebe M, Bekele Y, Aseffa A, Wabii G, Howe R. Impact of HIV co-infection on plasma level of cytokines and chemokines of pulmonary tuberculosis patients. BMC Infect Dis. 2014;14:125.
47. Cardoso TS, Costa JO, Reis EA, Silveira MR, Bonolo PF, Santos SFD, et al. Which antiretroviral regimen is associated with higher adherence in Brazil? A comparison of single, multi, and dolutegravir-based regimens. Cad Saude Publica. 2019;35(9):e0015518.
48. Huang Y, Huang X, Chen H, Wu H, Chen Y. Efficacy and safety of raltegravir-based dual therapy in AIDS patients: a meta-analysis of Randomized Controlled Trials. Front Pharmacol. 2019;10:1225.
49. Dutertre M, Cuzin L, Pugliese P, Joly V, Valantin MA, Cotte L, et al. Initiation of ART based on integrase inhibitors increases the risk of IRIS. Topics Antiviral Med. 2017;25(1):313–45.
50. Crucciani M, Parisi SG. Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: a systematic review and meta-analysis. PLoS ONE. 2019;14(9):e0222229.
51. Snedecor SJ, Radford ML, Kratochvil D, Grove R, Punekar YS. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naive patients infected with HIV-1: a systematic review and network meta-analysis. BMC Infect Dis. 2019;19(1):484.
52. Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV. 2019;6(2):e10–20.
53. Jiang J, Xu X, Guo W, Su J, Huang J, Liang B, et al. Dolutegravir (DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. AIDS Res Ther. 2019;16(3):118.
54. Nabasise R, Musauzi J, Deni P, Aber F, Lamorde M, Dooley KE, et al. Pharmacokinetics, SAFevity/tolerability, and Efficacy of high-dose Rifampicin in tuberculosis/HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). Trials. 2020;21(1):1–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.